{"id":942234,"date":"2026-03-05T11:04:38","date_gmt":"2026-03-05T16:04:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/"},"modified":"2026-03-05T11:04:38","modified_gmt":"2026-03-05T16:04:38","slug":"verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/","title":{"rendered":"Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WEST CHESTER, Pa., March  05, 2026  (GLOBE NEWSWIRE) &#8212; Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d or \u201cthe Company\u201d) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company&#8217;s financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update.<\/p>\n<p>Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.<\/p>\n<p>A live audio webcast of the call can also be accessed by visiting the investor relations section of the Company\u2019s website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lzb4V6Lzo0wtWrCqhxsJJiYITLBd6DyOUDNsRpPBCF8FnUGnEgaL4tntV2xTnLEsKx8VSDSbTcoiEhMTXiCHnA==\" rel=\"nofollow\" target=\"_blank\">www.verrica.com<\/a>, or by clicking <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8ntD7dN2j9h8SMVdy5FvKEikqeFW5l1vs1GWw9AvXfTy4Zp6ncO-qpTVo-iI9HRYEWlkXdgoa-sIvHihp12QXSt9EcvXwS5EFs2W6wLP1nP53wJqCgTNCrtd-7Su84Nlrli8cg9NrjC86UScPImamA==\" rel=\"nofollow\" target=\"_blank\">here<\/a>. A replay of the webcast will be archived on Verrica\u2019s website for 90 days following the event.<\/p>\n<p>\n        <strong>About Verrica Pharmaceuticals Inc.<\/strong><br \/>\n        <br \/>Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica\u2019s product YCANTH<sup>\u00ae<\/sup>\u00a0(VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH<sup>\u00ae<\/sup> (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lzb4V6Lzo0wtWrCqhxsJJluEP_B0B7GZTk41md0r0Vr7u_gS61jJsT9JIYRKY44oLamAtfLYYzZgW8CZoMLI-neTYyTkZDzRjNzkU11nsmg=\" rel=\"nofollow\" target=\"_blank\">www.verrica.com<\/a>.<\/p>\n<p>\n        <strong>FOR MORE INFORMATION, PLEASE CONTACT:<\/strong>\n      <\/p>\n<p>Investors:<\/p>\n<p>\n        <strong>John J Kirby<\/strong><br \/>\n        <br \/>Interim Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PVBr7rXSBnttHUx5DljZKKfx3eXQMFwpRpKpHvzb3yp2Dt482TWlle9Fb5d3zXQfzn19Sv2Ar_CLDE6cfp7VOWO18OBxGua-wYHyqjVY_0o=\" rel=\"nofollow\" target=\"_blank\">jkirby@verrica.com<\/a><\/p>\n<p>\n        <strong>Kevin Gardner<\/strong><br \/>\n        <br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rJV_Wha2pHw4zRmjyHVtXHHLElw4RJTnODjsMUUJWlAIws487YxNAlTzUF1HCXieq_iIn5Ci71zp648AzQ3DYziYx8_hh-RqAKokzUnM-VpA6rJBZSssGMtX79oNa2Oa\" rel=\"nofollow\" target=\"_blank\">kgardner@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjE3NSM3NDY4Njk2IzIxMjA3NDg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTNlZDZlZWQtNWViOS00NjYwLWI4NGItMGM2NWMwYzBhZWRiLTExMzIzMTktMjAyNi0wMy0wNS1lbg==\/tiny\/Verrica-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) &#8212; Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d or \u201cthe Company\u201d) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company&#8217;s financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register. A live audio webcast of the call &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-942234","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) &#8212; Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d or \u201cthe Company\u201d) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company&#8217;s financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register. A live audio webcast of the call &hellip; Continue reading &quot;Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T16:04:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjE3NSM3NDY4Njk2IzIxMjA3NDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026\",\"datePublished\":\"2026-03-05T16:04:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\\\/\"},\"wordCount\":325,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjE3NSM3NDY4Njk2IzIxMjA3NDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\\\/\",\"name\":\"Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjE3NSM3NDY4Njk2IzIxMjA3NDg=\",\"datePublished\":\"2026-03-05T16:04:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjE3NSM3NDY4Njk2IzIxMjA3NDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjE3NSM3NDY4Njk2IzIxMjA3NDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/","og_locale":"en_US","og_type":"article","og_title":"Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 - Market Newsdesk","og_description":"WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) &#8212; Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d or \u201cthe Company\u201d) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company&#8217;s financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register. A live audio webcast of the call &hellip; Continue reading \"Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-05T16:04:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjE3NSM3NDY4Njk2IzIxMjA3NDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026","datePublished":"2026-03-05T16:04:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/"},"wordCount":325,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjE3NSM3NDY4Njk2IzIxMjA3NDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/","name":"Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjE3NSM3NDY4Njk2IzIxMjA3NDg=","datePublished":"2026-03-05T16:04:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjE3NSM3NDY4Njk2IzIxMjA3NDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjE3NSM3NDY4Njk2IzIxMjA3NDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942234","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=942234"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942234\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=942234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=942234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=942234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}